Inovio Pharmaceuticals Inc INO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INOVIO Reports Inducement Grants Under Inducement Plan
-
INOVIO to Present at Upcoming Scientific Conferences
-
INOVIO to Present at Upcoming Scientific Conference
-
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
-
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
INOVIO Reports Inducement Grant Under Inducement Plan
-
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
-
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
Trading Information
- Previous Close Price
- $5.65
- Day Range
- $5.55–5.79
- 52-Week Range
- $3.89–14.75
- Bid/Ask
- $4.86 / $6.20
- Market Cap
- $144.10 Mil
- Volume/Avg
- 400 / 319,926
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 224.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 122
- Website
- https://www.inovio.com
Comparables
Valuation
|
Metric
|
INO
|
ACLX
|
PCVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.49 | 8.61 | 6.20 |
Price/Sales | 224.15 | 27.51 | — |
Price/Cash Flow | — | 507.02 | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INO
|
ACLX
|
PCVX
|
|---|---|---|---|
Quick Ratio | 4.25 | 5.85 | 17.75 |
Current Ratio | 4.45 | 6.01 | 17.88 |
Interest Coverage | −164.72 | −28.35 | — |
Quick Ratio
INO
ACLX
PCVX
Profitability
|
Metric
|
INO
|
ACLX
|
PCVX
|
|---|---|---|---|
Return on Assets (Normalized) | −60.05% | −1.88% | −20.76% |
Return on Equity (Normalized) | −83.82% | −3.31% | −22.15% |
Return on Invested Capital (Normalized) | −74.38% | −7.10% | −26.84% |
Return on Assets
INO
ACLX
PCVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jnfdncgj | Ckyxx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jrlwbcvb | Blxzps | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mwdszznhh | Knrrnr | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vhgxygrkn | Gqtvl | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Jwqyfqnv | Gstw | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Rrvcdwvdt | Lkmb | $29.2 Bil | |||
| Moderna Inc
MRNA
| Nwqgvjyz | Npwq | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Hgbrlnjq | Rrkl | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qlqssfrsj | Qkqtzy | $13.2 Bil | |||
| Incyte Corp
INCY
| Shczhzj | Ttrph | $13.0 Bil |
United States